ALLO logo

Allogene Therapeutics (ALLO)

Profile

Full Name

Allogene Therapeutics, Inc.

Ticker Symbol

ALLO

Exchange

NASDAQ

Sector

Healthcare

Industry

Biotechnology

Country

United States

IPO

October 11, 2018

Indexes

Not included

Website

http://www.allogene.com

Employees

226

Key Details

Price

$1.45(+5.84%)

Market cap

$315.03M(Small cap)

Last Dividend

-

TTM Dividend yield

-

Annual revenue

$22.00K(-76.84% YoY)

Annual EPS

-$1.32(+36.84% YoY)

PE ratio

-

Next earnings date

May 13, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$1.45
ALLO price is $1.45

30-Day Relative Volume

0.64
ALLO 30-day relative volume is 0.64

Price Performance

Price Today change

+5.84%
ALLO price is up +5.84% today

Price YTD change

-31.92%
ALLO price is down -31.92% since January 1st

Price 1-year change

-63.66%
ALLO price is down -63.66% year-on-year

Price 3-year change

-82.88%
ALLO price is down -82.88% over the past 3 years

Price Range

Price All-time high

$55.00
ALLO price is currently -97.36% below its historical high of $55.00

Price 3-year low

$1.23
ALLO price is currently +17.89% above its 3-year low

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market cap

$315.03M
ALLO market capitalization is $315.03 million

Market cap 3-year change

-74.09%
ALLO market capitalization is down -74.09% over the past 3 years

Market cap All-time high

$6.77B
ALLO market capitalization is currently -95.35% below its historical high of $6.77 billion

Market cap sector rank

63.6%
ALLO market capitalization is higher than 63.6% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

+27.46%
ALLO shares outstanding is up +27.46% year-on-year

Shares Outstanding 3-Year Change

+51.33%
ALLO shares outstanding is up +51.33% over the past 3 years

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

1.10
ALLO beta is 1.10

200-day SMA

$2.31
ALLO price is currently -37.14% below its 200-day simple moving average

50-day SMA

$1.76
ALLO price is currently -17.52% below its 50-day simple moving average

RSI

41.95
ALLO 14-day relative strength index is 41.95

Volume

0.64
ALLO 30-day relative volume is 0.64

ATR

$0.17
ALLO average true range is $0.17

10-day Historical Volatility

78.75%
ALLO 10-day historical volatility is 78.75%

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

$22.00K
ALLO annual revenue is $22.00 thousand

Revenue Analysts estimate

$12.86K
ALLO annual revenue is currently +71.07% higher than the consensus analysts' forecast

Revenue 1-year change

-76.84%
ALLO annual revenue is down -76.84% year-on-year

Revenue Sector rank

3.36%
ALLO annual revenue is higher than 3.36% of companies in Healthcare sector

EPS

EPS

-$1.32
ALLO annual earnings per share is -$1.32

EPS Analysts estimate

-$1.12
ALLO annual earnings per share is currently +17.44% higher than the consensus analysts' forecast

EPS 1-year change

+36.84%
ALLO annual earnings per share is up +36.84% year-on-year

EPS Sector rank

49.13%
ALLO annual earnings per share is higher than 49.13% of companies in Healthcare sector

Profit

Gross profit

-
ALLO annual gross profit value is unknown

Gross margin

-
ALLO annual gross profit margin value is unknown

Operating profit

-$257.48M
ALLO annual operating income is -$257.48 million

Operating margin

-1.17M%
ALLO annual operating profit margin is -1.17 million%

Net income

-$257.59M
ALLO annual net profit is -$257.59 million

Net margin

-1.17M%
ALLO annual net profit margin is -1.17 million%

Expenses

Total expenses

$257.50M
ALLO annual total expenses is $257.50 million

Operating expenses

$257.50M
ALLO annual total operating expenses is $257.50 million

Cost of goods sold

-
ALLO annual cost of goods sold value is unknown

Selling, general & administrative expenses

$65.20M
ALLO annual SGA is $65.20 million

Depreciation and amortization

$13.64M
ALLO annual depreciation & amortization is $13.64 million

Interest expense

$181.00K
ALLO annual interest expense is $181.00 thousand

Income tax

$443.00K
ALLO annual income tax is $443.00 thousand

EBIT & EBITDA

EBIT

-$256.97M
ALLO annual earnings before interest & taxes is -$256.97 million

EBITDA

-$243.33M
ALLO annual EBITDA is -$243.33 million

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total assets

$548.71M
ALLO annual total assets is $548.71 million

Non current assets

$245.32M
ALLO annual long term assets is $245.32 million

Current assets

$303.39M
ALLO annual total current assets is $303.39 million

Cash and cash equivalents

$75.22M
ALLO annual cash & cash equivalents is $75.22 million

Accounts receivable

-
ALLO annual accounts receivable value is unknown

Inventory

-
ALLO annual inventory value is unknown

Liabilities

Total liabilities

$126.53M
ALLO annual total liabilities is $126.53 million

Long term liabilities

$91.01M
ALLO annual total long term liabilities is $91.01 million

Current liabilities

$35.52M
ALLO annual total current liabilities is $35.52 million

Accounts payable

$5.39M
ALLO annual accounts payable is $5.39 million

Debt

Total debt

$90.76M
ALLO annual total debt is $90.76 million

Total debt 1-year change

-4.59%
ALLO annual total debt is down -4.59% year-on-year

Long term debt

$83.25M
ALLO annual long term debt is $83.25 million

Short term debt

$7.51M
ALLO annual short term debt is $7.51 million

Equity & Capital

Shareholders equity

$422.18M
ALLO annual stockholders equity is $422.18 million

Book value

$422.18M
ALLO annual book value is $422.18 million

Retained earnings

-$1.82B
ALLO annual retained earnings is -$1.82 billion

Working capital

$267.86M
ALLO annual working capital is $267.86 million

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash from operations

-$200.30M
ALLO annual cash flow from operations is -$200.30 million

Cash from operations 1-year change

+15.75%
ALLO annual cash flow from operations is up +15.75% year-on-year

Cash from investing

$75.69M
ALLO annual cash flow from investing activities is $75.69 million

Cash from investing 1-year change

-53.65%
ALLO annual cash flow from investing activities is down -53.65% year-on-year

Cash from financing

$116.67M
ALLO annual cash flow from financing activities is $116.67 million

Cash from financing 1-year change

+21.92%
ALLO annual cash flow from financing activities is up +21.92% year-on-year

CAPEX

CAPEX

$694.00K
ALLO annual capital expenditures is $694.00 thousand

CAPEX 1-year change

-54.22%
ALLO annual capital expenditures is down -54.22% year-on-year

Free Cash Flow

Free cash flow

-$200.99M
ALLO annual free cash flow is -$200.99 million

Free cash flow 1-year change

+15.99%
ALLO annual free cash flow is up +15.99% year-on-year

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross margin

-
ALLO annual gross profit margin value is unknown

Operating margin

-1.17M%
ALLO annual operating profit margin is -1.17 million%

Net margin

-1.17M%
ALLO annual net profit margin is -1.17 million%

ROA & ROE

ROA

-43.24%
ALLO annual return on assets is -43.24%

ROE

-55.13%
ALLO annual return on equity is -55.13%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE ratio

-
ALLO price to earnings ratio value is unknown

PE ratio Sector rank

-
ALLO price to earnings ratio is unknown

PB Ratio

PB ratio

0.75
ALLO price to book ratio is 0.75

PB ratio Sector rank

38.32%
ALLO price to book ratio is higher than 38.32% of companies in Healthcare sector

PS Ratio

PS ratio

-
ALLO price to sales ratio value is unknown

PS ratio Sector rank

-
ALLO price to sales ratio is unknown

Enterprise value

Enterprise value

$330.57M
ALLO enterprise value is $330.57 million

Enterprise value Sector rank

64.55%
ALLO enterprise value is higher than 64.55% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-1.33
ALLO EV/EBITDA is -1.33

EV/EBITDA Sector rank

38.11%
ALLO EV/EBITDA is higher than 38.11% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current ratio

8.54
ALLO annual current ratio is 8.54

Quick ratio

-
ALLO annual quick ratio value is unknown

Leverage

Debt to equity

0.00
ALLO annual debt to equity ratio is 0.00

Interest coverage ratio

-1419.70
ALLO annual interest coverage ratio is -1419.70

Risk & Stability

Piotroski F-Score

-
ALLO piotroski f-score value is unknown

Altman Z-Score

-4.11
ALLO altman z-score is -4.11

Analyst ratings

Recent major analysts updates

Mar 19, 25 HC Wainwright & Co.
Buy
Mar 14, 25 RBC Capital
Outperform
Mar 14, 25 Citizens Capital Markets
Market Outperform
Mar 14, 25 Canaccord Genuity
Buy
Nov 14, 24 Piper Sandler
Overweight
Nov 8, 24 HC Wainwright & Co.
Buy
Oct 30, 24 HC Wainwright & Co.
Buy
Aug 15, 24 HC Wainwright & Co.
Buy
Aug 9, 24 Truist Securities
Buy
Aug 9, 24 Citigroup
Buy

Institutional Ownership

Similar stocks

TRDA logo
Entrada Therapeutics (TRDA)
IVA logo
Inventiva SA (IVA)
ERAS logo
Erasca (ERAS)
AUTL logo
Autolus Therapeutics (AUTL)
MREO logo
Mereo BioPharma (MREO)
RIGL logo
Rigel Pharmaceuticals (RIGL)
SPOK logo
Spok Holdings (SPOK)
ORIC logo
ORIC Pharmaceuticals (ORIC)
TKNO logo
Alpha Teknova (TKNO)
  • What is the ticker symbol for Allogene Therapeutics?
  • Does Allogene Therapeutics pay dividends?
  • What sector is Allogene Therapeutics in?
  • What industry is Allogene Therapeutics in?
  • What country is Allogene Therapeutics based in?
  • When did Allogene Therapeutics go public?
  • Is Allogene Therapeutics in the S&P 500?
  • Is Allogene Therapeutics in the NASDAQ 100?
  • Is Allogene Therapeutics in the Dow Jones?
  • When was Allogene Therapeutics's last earnings report?
  • When does Allogene Therapeutics report earnings?
  • Should I buy Allogene Therapeutics stock now?

What is the ticker symbol for Allogene Therapeutics?

The ticker symbol for Allogene Therapeutics is NASDAQ:ALLO

Does Allogene Therapeutics pay dividends?

No, Allogene Therapeutics does not pay dividends

What sector is Allogene Therapeutics in?

Allogene Therapeutics is in the Healthcare sector

What industry is Allogene Therapeutics in?

Allogene Therapeutics is in the Biotechnology industry

What country is Allogene Therapeutics based in?

Allogene Therapeutics is headquartered in United States

When did Allogene Therapeutics go public?

Allogene Therapeutics's initial public offering (IPO) was on October 11, 2018

Is Allogene Therapeutics in the S&P 500?

No, Allogene Therapeutics is not included in the S&P 500 index

Is Allogene Therapeutics in the NASDAQ 100?

No, Allogene Therapeutics is not included in the NASDAQ 100 index

Is Allogene Therapeutics in the Dow Jones?

No, Allogene Therapeutics is not included in the Dow Jones index

When was Allogene Therapeutics's last earnings report?

Allogene Therapeutics's most recent earnings report was on Mar 13, 2025

When does Allogene Therapeutics report earnings?

The next expected earnings date for Allogene Therapeutics is May 13, 2025

Should I buy Allogene Therapeutics stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page